Studies pioneered by Dowsett and co-workers have revealed that a drop in tumor Ki67 expression following 2 weeks of endocrine treatment may predict recurrence-free survival [9] and guide the selection of correct adjuvant treatment [10]. The gene discussed is MKI67; the disease is neoplasm.